Standard Chem & Pharm CO., LTD. (1720.TW)
TWD 57.2
(-0.35%)
TWD 57.2
(-0.35%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 6.23 Billion TWD | 6.64% |
| 2022 | 5.85 Billion TWD | 27.09% |
| 2021 | 4.6 Billion TWD | 6.94% |
| 2020 | 4.3 Billion TWD | 9.35% |
| 2019 | 3.93 Billion TWD | 10.19% |
| 2018 | 3.57 Billion TWD | -7.16% |
| 2017 | 3.84 Billion TWD | 4.76% |
| 2016 | 3.67 Billion TWD | 10.61% |
| 2015 | 3.32 Billion TWD | 0.78% |
| 2014 | 3.29 Billion TWD | 7.91% |
| 2013 | 3.05 Billion TWD | -9.48% |
| 2012 | 3.37 Billion TWD | 1.25% |
| 2011 | 3.33 Billion TWD | 15.12% |
| 2010 | 2.89 Billion TWD | 26.69% |
| 2009 | 2.28 Billion TWD | 4.69% |
| 2008 | 2.18 Billion TWD | 8.47% |
| 2007 | 2.01 Billion TWD | 4.54% |
| 2006 | 1.92 Billion TWD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.61 Billion TWD | 1.34% |
| 2024 Q2 | 1.76 Billion TWD | 9.08% |
| 2023 Q4 | 1.59 Billion TWD | -3.24% |
| 2023 Q2 | 1.5 Billion TWD | 1.07% |
| 2023 Q1 | 1.49 Billion TWD | -5.7% |
| 2023 Q3 | 1.64 Billion TWD | 9.05% |
| 2023 FY | 6.23 Billion TWD | 6.64% |
| 2022 Q4 | 1.58 Billion TWD | 2.15% |
| 2022 FY | 5.85 Billion TWD | 27.09% |
| 2022 Q3 | 1.54 Billion TWD | 4.65% |
| 2022 Q2 | 1.48 Billion TWD | 19.71% |
| 2022 Q1 | 1.23 Billion TWD | 0.33% |
| 2021 Q3 | 1.12 Billion TWD | -2.46% |
| 2021 Q4 | 1.23 Billion TWD | 10.01% |
| 2021 Q1 | 1.1 Billion TWD | -1.47% |
| 2021 FY | 4.6 Billion TWD | 6.94% |
| 2021 Q2 | 1.14 Billion TWD | 4.35% |
| 2020 Q1 | 1.03 Billion TWD | 0.31% |
| 2020 Q4 | 1.11 Billion TWD | 6.91% |
| 2020 Q3 | 1.04 Billion TWD | -5.66% |
| 2020 FY | 4.3 Billion TWD | 9.35% |
| 2020 Q2 | 1.1 Billion TWD | 7.12% |
| 2019 Q2 | 1.01 Billion TWD | 19.46% |
| 2019 FY | 3.93 Billion TWD | 10.19% |
| 2019 Q4 | 1.03 Billion TWD | -1.68% |
| 2019 Q3 | 1.04 Billion TWD | 3.76% |
| 2019 Q1 | 846.17 Million TWD | -15.28% |
| 2018 FY | 3.57 Billion TWD | -7.16% |
| 2018 Q4 | 998.78 Million TWD | 9.35% |
| 2018 Q3 | 913.35 Million TWD | 1.74% |
| 2018 Q2 | 897.69 Million TWD | 17.61% |
| 2018 Q1 | 763.26 Million TWD | -15.74% |
| 2017 FY | 3.84 Billion TWD | 4.76% |
| 2017 Q1 | 909.93 Million TWD | -4.71% |
| 2017 Q4 | 905.82 Million TWD | -14.28% |
| 2017 Q3 | 1.05 Billion TWD | 8.25% |
| 2017 Q2 | 976.17 Million TWD | 7.28% |
| 2016 Q2 | 940.23 Million TWD | 9.45% |
| 2016 FY | 3.67 Billion TWD | 10.61% |
| 2016 Q1 | 859.02 Million TWD | -6.26% |
| 2016 Q4 | 954.87 Million TWD | 3.83% |
| 2016 Q3 | 919.66 Million TWD | -2.19% |
| 2015 FY | 3.32 Billion TWD | 0.78% |
| 2015 Q4 | 916.37 Million TWD | 12.6% |
| 2015 Q3 | 813.82 Million TWD | 3.73% |
| 2015 Q2 | 784.59 Million TWD | -2.73% |
| 2015 Q1 | 806.57 Million TWD | -7.82% |
| 2014 Q4 | 875.03 Million TWD | 8.19% |
| 2014 FY | 3.29 Billion TWD | 7.91% |
| 2014 Q1 | 798.17 Million TWD | 2.0% |
| 2014 Q2 | 813.63 Million TWD | 1.94% |
| 2014 Q3 | 808.81 Million TWD | -0.59% |
| 2013 Q4 | 782.56 Million TWD | 7.16% |
| 2013 FY | 3.05 Billion TWD | -9.48% |
| 2013 Q3 | 730.28 Million TWD | -3.6% |
| 2013 Q1 | 783.61 Million TWD | -16.27% |
| 2013 Q2 | 757.52 Million TWD | -3.33% |
| 2012 Q3 | 800.35 Million TWD | -5.52% |
| 2012 Q4 | 935.84 Million TWD | 16.93% |
| 2012 Q2 | 847.15 Million TWD | 7.17% |
| 2012 FY | 3.37 Billion TWD | 1.25% |
| 2012 Q1 | 790.45 Million TWD | -14.6% |
| 2011 Q3 | 784.53 Million TWD | -4.86% |
| 2011 Q4 | 925.62 Million TWD | 17.98% |
| 2011 FY | 3.33 Billion TWD | 15.12% |
| 2011 Q1 | 797.28 Million TWD | -26.19% |
| 2011 Q2 | 824.56 Million TWD | 3.42% |
| 2010 Q1 | 560.7 Million TWD | 0.0% |
| 2010 FY | 2.89 Billion TWD | 26.69% |
| 2010 Q4 | 1.08 Billion TWD | 72.13% |
| 2010 Q3 | 627.52 Million TWD | 0.23% |
| 2010 Q2 | 626.07 Million TWD | 11.66% |
| 2009 FY | 2.28 Billion TWD | 4.69% |
| 2008 FY | 2.18 Billion TWD | 8.47% |
| 2007 FY | 2.01 Billion TWD | 4.54% |
| 2006 FY | 1.92 Billion TWD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Grape King Bio Ltd | 10.63 Billion TWD | 41.317% |
| Maywufa Company Ltd. | 1.3 Billion TWD | -379.716% |
| ScinoPharm Taiwan, Ltd. | 3.18 Billion TWD | -95.844% |
| Lotus Pharmaceutical Co., Ltd. | 16.95 Billion TWD | 63.205% |
| LIWANLI Innovation Co., Ltd. | 38.88 Million TWD | -15945.897% |
| YungShin Global Holding Corporation | 7.02 Billion TWD | 11.215% |
| PhytoHealth Corporation | 162.48 Million TWD | -3740.117% |
| SCI Pharmtech, Inc. | 1.2 Billion TWD | -418.185% |
| Formosa Laboratories, Inc. | 4.36 Billion TWD | -43.099% |
| PharmaEssentia Corporation | 5.1 Billion TWD | -22.214% |
| Bora Pharmaceuticals Co., LTD. | 14.2 Billion TWD | 56.058% |